Samuel J Klempner
Overview
Explore the profile of Samuel J Klempner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
152
Citations
4096
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Tian J, Chen J, Chao S, Pelka K, Giannakis M, Hess J, et al.
Nat Med
. 2023 Jan;
29(2):458-466.
PMID: 36702949
While BRAF inhibitor combinations with EGFR and/or MEK inhibitors have improved clinical efficacy in BRAF colorectal cancer (CRC), response rates remain low and lack durability. Preclinical data suggest that BRAF/MAPK...
32.
Quintanilha J, Graf R, Fisher V, Oxnard G, Ellis H, Panarelli N, et al.
JAMA Netw Open
. 2023 Jan;
6(1):e2252244.
PMID: 36689222
Importance: The KEYNOTE-177 trial demonstrated that patients with metastatic colorectal cancer (MCRC) with high microsatellite instability (MSI-H) and/or mismatch repair deficiency (DMMR) have better outcomes when receiving first-line immune checkpoint...
33.
Sun Y, Revach O, Anderson S, Kessler E, Wolfe C, Jenney A, et al.
Nature
. 2023 Jan;
615(7950):158-167.
PMID: 36634707
Despite the success of PD-1 blockade in melanoma and other cancers, effective treatment strategies to overcome resistance to cancer immunotherapy are lacking. Here we identify the innate immune kinase TANK-binding...
34.
Yaeger R, Weiss J, Pelster M, Spira A, Barve M, Ou S, et al.
N Engl J Med
. 2022 Dec;
388(1):44-54.
PMID: 36546659
Background: Adagrasib, an oral small-molecule inhibitor of mutant KRAS G12C protein, has shown clinical activity in pretreated patients with several tumor types, including colorectal cancer. Preclinical studies suggest that combining...
35.
Hachey S, Sobrino A, Lee J, Jafari M, Klempner S, Puttock E, et al.
Transl Res
. 2022 Dec;
255:97-108.
PMID: 36481562
Accurately modeling tumor biology and testing novel therapies on patient-derived cells is critically important to developing therapeutic regimens personalized to a patient's specific disease. The vascularized microtumor (VMT), or "tumor-on-a-chip,"...
36.
Huffman B, Aushev V, Budde G, Chao J, Dayyani F, Hanna D, et al.
JCO Precis Oncol
. 2022 Dec;
6:e2200420.
PMID: 36480779
Purpose: Circulating tumor DNA (ctDNA) analyses allow for postoperative risk stratification in patients with curatively treated colon and breast cancers. Use of ctDNA in esophagogastric cancers (EGC) is less characterized...
37.
Staller K, Badran Y, Rosman D, Klempner S, Judelson R
N Engl J Med
. 2022 Oct;
387(15):1415-1424.
PMID: 36239648
No abstract available.
38.
Powderly J, Klempner S, Naing A, Bendell J, Garrido-Laguna I, Catenacci D, et al.
Oncologist
. 2022 Sep;
27(11):905-e848.
PMID: 36156099
Background: Epacadostat, an oral, selective inhibitor of IDO1, has shown activity when administered with pembrolizumab. We evaluated the addition of chemotherapy to epacadostat and pembrolizumab in patients with advanced or...
39.
Maron S, Moya S, Morano F, Emmett M, Chou J, Sabwa S, et al.
J Clin Oncol
. 2022 Mar;
40(22):2458-2467.
PMID: 35349370
Purpose: Subset analyses from phase III evaluation of epidermal growth factor receptor inhibition (EGFRi) suggest improved outcomes in patients with amplified gastroesophageal adenocarcinoma (GEA), but large-scale analyses are lacking. This...
40.
Midthun L, Kim S, Hendifar A, Osipov A, Klempner S, Chao J, et al.
World J Gastrointest Oncol
. 2022 Mar;
14(2):511-524.
PMID: 35317320
Background: Chemotherapy has long been shown to confer a survival benefit in patients with metastatic esophageal cancer. However, not all patients with metastatic disease receive chemotherapy. Aim: To evaluate a...